肿瘤异质性与抗肿瘤靶向药物的耐药性  

Tumor heterogeneity and drug resistance of targeted antitumor agents

作　　者：何琪杨[1] 

机构地区：[1]中国医学科学院北京协和医学院医药生物技术研究所,北京100050

出　　处：《药学学报》2016年第2期197-201,共5页Acta Pharmaceutica Sinica

基　　金：国家自然科学基金资助项目(81273553)

摘　　要：抗肿瘤靶向药物的广泛应用极大地提高了肿瘤的治疗效果,但部分患者在治疗后6-12个月出现的耐药性往往导致治疗失败。产生耐药性的原因主要是肿瘤的异质性。肿瘤异质性与肿瘤干细胞的发生、遗传物质不稳定、细胞间竞争和随机性相关。有多种机制参与肿瘤细胞对靶向药物的耐药性。肿瘤异质性和耐药性对肿瘤精准治疗是一种挑战,需要在研发抗肿瘤新药中予以关注。The popular application of targeted antitumor agents has greatly improved the efficacies of tumor therapy. However, some patients develop drug resistance after the administration with them for six to twelve months, leading to the failure of treatment. The cause of it is mainly due to tumor heterogeneity. The genesis of tumor heterogeneity is closely associated with tumor stem cells, genetic instability, cell competition and stochastic events. There are a lot of mechanisms involved in the drug resistance to the targeted agents. Tumor heterogeneity and drug resistance are great challenges for precision oncology and are taken account for the process of research and development of new antitumor agents.

关 键 词：肿瘤异质性 抗肿瘤靶向药物 耐药性 生物标志物 精准医学 

分 类 号：R966[医药卫生—药理学]